ATE469644T1 - Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung - Google Patents

Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung

Info

Publication number
ATE469644T1
ATE469644T1 AT01982812T AT01982812T ATE469644T1 AT E469644 T1 ATE469644 T1 AT E469644T1 AT 01982812 T AT01982812 T AT 01982812T AT 01982812 T AT01982812 T AT 01982812T AT E469644 T1 ATE469644 T1 AT E469644T1
Authority
AT
Austria
Prior art keywords
polyethylene glycol
copolyvidone
coated
indenoä5
ethylupropionamide
Prior art date
Application number
AT01982812T
Other languages
English (en)
Inventor
Hajime Ishida
Makoto Fukuta
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE469644T1 publication Critical patent/ATE469644T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01982812T 2000-11-17 2001-11-16 Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung ATE469644T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000351223 2000-11-17
PCT/JP2001/010016 WO2002040054A1 (en) 2000-11-17 2001-11-16 Pharmaceutical preparation containing copolyvidone

Publications (1)

Publication Number Publication Date
ATE469644T1 true ATE469644T1 (de) 2010-06-15

Family

ID=18824316

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01982812T ATE469644T1 (de) 2000-11-17 2001-11-16 Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung

Country Status (7)

Country Link
US (3) US20040018239A1 (de)
EP (2) EP1334732B1 (de)
AT (1) ATE469644T1 (de)
AU (1) AU2002214305A1 (de)
CA (2) CA2650698C (de)
DE (1) DE60142305D1 (de)
WO (1) WO2002040054A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2004339162A (ja) * 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd 難溶性薬物を含む医薬用固形製剤とその製造方法
MXPA06000524A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
EP1742630A4 (de) * 2004-04-16 2010-01-20 Santarus Inc Kombination aus protonenpumpenhemmer, puffermittel und prokinetischem wirkstoff
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
JP5315611B2 (ja) * 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
TWI400220B (zh) * 2004-09-13 2013-07-01 Takeda Pharmaceutical 光活性胺衍生物的製法
JP5220408B2 (ja) * 2005-06-22 2013-06-26 武田薬品工業株式会社 難溶性の有効成分を含有する錠剤
AR061478A1 (es) 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CN104546746A (zh) * 2013-10-28 2015-04-29 南京长澳医药科技有限公司 一种雷美替胺片剂及其制备工艺
US10713458B2 (en) 2016-05-23 2020-07-14 InSyte Systems Integrated light emitting display and sensors for detecting biologic characteristics
US10931859B2 (en) 2016-05-23 2021-02-23 InSyte Systems Light emitter and sensors for detecting biologic characteristics

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617328A1 (de) * 1966-07-28 1971-06-03 Knecht Adolf O Dr Neue,zuckerfreie UEberzuege fuer Tabletten und Drageekerne
JPS456558B1 (de) * 1966-12-21 1970-03-05
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
HUT54035A (en) * 1989-06-22 1991-01-28 Chinoin Gyogyszer Es Vegyeszet Process for coating labile pharmaceutical active components for protecting from oxygen and humidity
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5401562A (en) * 1992-03-27 1995-03-28 Fuji Photo Film Co., Ltd. Paper material for photosensitive materials and method of producing the same
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
ES2175350T5 (es) * 1996-03-08 2008-12-16 Takeda Pharmaceutical Company Limited Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
ES2300119T3 (es) * 1997-02-27 2008-06-01 Takeda Pharmaceutical Company Limited Compuestos de amina, su produccion y su uso como inhibidores de la produccion de beta-amiloide.
KR100517006B1 (ko) * 1997-04-28 2005-09-27 닛토덴코 가부시키가이샤 광학 활성 단량체를 포함하는 측쇄형 액정 중합체, 및 이를 포함하는 광학 소자
CA2261787C (en) * 1997-05-30 2006-11-14 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
ID26395A (id) * 1998-05-15 2000-12-21 Warner Lambert Comapny Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
EP1100508B8 (de) * 1998-06-09 2004-01-07 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent

Also Published As

Publication number Publication date
EP2305219A1 (de) 2011-04-06
WO2002040054A1 (en) 2002-05-23
US20040018239A1 (en) 2004-01-29
CA2650698C (en) 2013-05-28
EP1334732A4 (de) 2006-03-15
DE60142305D1 (de) 2010-07-15
AU2002214305A1 (en) 2002-05-27
EP1334732B1 (de) 2010-06-02
US20170020841A1 (en) 2017-01-26
US20090274733A1 (en) 2009-11-05
US10098866B2 (en) 2018-10-16
CA2650698A1 (en) 2002-05-23
CA2428817A1 (en) 2002-05-23
EP1334732A1 (de) 2003-08-13
CA2428817C (en) 2010-06-01

Similar Documents

Publication Publication Date Title
ATE469644T1 (de) Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
ATE112961T1 (de) Cimetidin enthaltende arzneimittel.
DE69427472D1 (de) Arzneimittel mit kontrollierter Wirkstoffabgabe
GR1002564B (el) Στερεα απο του στοματος χορηγουμενη φαρμακευτικη μορφη δοσιμετρησεως προγραμματισμενου ρυθμου απελευθερωσεως.
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
DE69805001D1 (de) Osmotische darreichungsform mit zwei mantelschichten
DE60005819D1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
DK136186A (da) Laegemiddelbaerer
DE69323442D1 (de) Flüssige pharmazeutische Formulierung mit verlängerter Wirkstoffabgabe
DE69638364D1 (de) Formulierungen mit kontrollierter abgabe (albuterol)
DE68902954D1 (de) Waessrige ueberzugsemulsion fuer pharmazeutische dosierungsformen.
FR2683146B1 (fr) Compositions pharmaceutiques a liberation reglee de la substance medicamenteuse.
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
PT1121144E (pt) Preparados de insulina concentrada estavel para administracao pulmonar
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
DE69521924D1 (de) Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid
DE69811278D1 (de) Gegen magensaft geschützte omeprazol-mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
AR029333A1 (es) Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinada
DE69228674D1 (de) Nichtsteroide-entzündungshemmende Arzneimittel und Decongestirum enthaltende Augenarzneimittelzusammensetzung
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
NO20011217D0 (no) Doseringsform omfattende væskeformulering
ATE290854T1 (de) Carbamazepinformulierung mit verzögerter freigabe
EP1221926A4 (de) Pharmazeutische zusammensetzungen mit schlecht löslichen arzneimittelwirkstoffen
ATE247981T1 (de) Proteinenthaltende pharmazeutische zubereitung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties